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Abstract
Background: Magnetic resonance imaging (MRI) of thigh muscles is increasingly used to assess disease activity and
damage extent in chronic myositis, but the validity of the findings is not clear. Here, the primary aim was to compare
thigh MRI findings in patients having chronic myositis associated with anti-synthetase syndrome (ASS) and in matched
healthy controls.
Methods: Cross-sectional analyses of thigh muscle MRI, muscular function and creatinine kinase (CK) were performed
in 68 ASS patients (median disease duration 71 months) and 67 controls matched for age and gender. MRI changes
associated with disease activity (edema in muscles and fascia) and damage (fatty replacement and muscle volume
reduction) were assessed semiquantitatively, giving a total MRI score of 0–78 (total edema 0–42 and total damage 0–36).
Results: ASS patients had higher total MRI score than the matched controls (14.1 versus 3.0; p < 0.001) and less muscle
strength (p < 0.001). Muscle edema was more frequent in ASS patients than controls (38% versus 12%), as was fatty
replacement (42% versus 4%). In ASS patients, we found that the total edema score correlated with CK, but 23% of the
patients with normal CK had score > 18. Muscle compartment analyses in ASS patients showed that muscle edema was
most pronounced anteriorly, while fatty replacement dominated posteriorly.
Conclusions: This study showed, for the first time, the magnitude of difference in muscle MRI findings between
chronic myositis cases and matched controls. In ASS patients, muscle MRI appeared to provide useful complementary
information to muscle strength and CK levels in the assessment of myositis.
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Background
Anti-synthetase syndrome (ASS), first described by
Marguerie et al. in 1990 [1], includes an anti-aminoacyl
t-RNA synthetase (aaRS) antibody, myositis, interstitial
lung disease (ILD), arthritis, Raynaud syndrome, mechanic
hands and fever. Eight aaRS antibodies have been detected
to date, the most common being anti-Jo1. Several sets of
ASS classification criteria have been proposed, most of
them with ILD and myositis as major disease items [2–4].
The impact of muscle involvement in ASS appears to
differ between anti- aaRS subtypes, with myositis being
most prevalent and pronounced in anti-Jo-1-positive
ASS [5, 6]. Overall, the reported frequencies of myo-
sitis in ASS range from 43 to 62% [6, 7], where the in-
cidence increases with disease duration [8]. In Jo-1-
positive ASS, polymyositis (PM) was reported as the
most frequent type of myositis, while dermatomyositis
(DM), including amyopathic or hypomyopathic DM,
seems to predominate in anti-Jo1-negative subsets [7].
Magnetic resonance imaging (MRI) of the muscles,
especially the thighs, is commonly used for clinical pur-
poses in myositis [9, 10]. As a diagnostic tool, MRI
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seems to be useful to differentiate between DM, PM, in-
clusion body myositis and non-inflammatory myopathies
[11–15]. Furthermore, because the inflammatory changes
in myositis may be patchy, MRI is useful to detect the best
possible location for muscle biopsy [16, 17]. Research on
the clinical utility of muscle MRI is expanding and recent
studies have indicated that it could be useful for assessing
disease activity in chronic myositis and possibly also treat-
ment responses [9, 18, 19].
The myositis component in ASS was described recently
as a distinct histological entity [20–22]. However, as far as
we know, there is no study investigating whether the acute
and chronic stages of ASS are marked by a specific muscle
MRI pattern. Importantly, because there are no bench-
mark studies available on the frequency and magnitude of
muscle MRI “abnormalities” in healthy populations, it has
been difficult to determine the validity of this imaging mo-
dality in acute and chronic myositis. Hence, the aims for
this study were: to describe and quantify muscle MRI
changes in a well-defined cohort of ASS patients, most of
them with established, chronic myositis, and in a gen-
der and age-matched cohort of healthy individuals; to
evaluate possible correlations between muscle MRI changes,
muscle enzyme levels and muscle strength in ASS patients
and controls; and to evaluate muscle outcome and possible
muscle MRI patterns in ASS and its subsets with different
anti-synthetase antibodies.
Methods
Definition of ASS and study population
The study cohort has been described elsewhere [23].
Briefly, the cohort included 68 ASS patients and 67
healthy age and sex-matched controls examined at Oslo
University Hospital between September 2011 and June
2014. All examinations were done concomitantly for
each participant. The ASS cohort was largely unselected,
and included all of the aaRS-positive myositis cases
identified in a recent population-based myositis study
from south-east Norway [24]. ASS was defined as follows:
a positive test of an anti-aaRS antibody; ILD according to
the American Thoracic Society [25]; and/or probable/
definite PM/DM according to the Bohan and Peter
criteria [26].
Serum antibody assays
Serum anti-histidyl tRNA synthetase (Jo-1) and anti-SSA
autoantibodies were detected by automated ELISA (EliA;
Phadia, Freiburg, Germany). Anti-threonyl (PL-7), anti-
alanyl (PL-12), anti-glycyl (EJ) and anti-isoleucyl (OJ)
tRNA synthetases and anti-Ro52 antibodies were detected
by line blot assay (Euroline Myositis kit; Euroimmune
Laboratory, Luebeck, Germany).
Muscle MRI of the thighs
All MRI scans were obtained on 1.5-T units (Siemens,
Erlangen, Germany) with coronal and axial T1-weighted
spin echo and short T1 inversion recovery (STIR) se-
quences of the thigh muscles. Participants were asked not
to exercise 24 hours before the examination. The muscles
were evaluated in the anterior, posterior and medial com-
partments and included muscles involved in hip flexion/
abduction and knee flexion/extension. Two musculoskel-
etal radiologists (EK, EM), unaware of the participant’s
status, analyzed the MRI scans together. If any disagree-
ment occurred, consensus was reached by discussion.
Muscle edema in each compartment was evaluated in
terms of extent and signal intensity, both variables using a
grading scale (0–3). For the extent of edema, grade 0 was
defined as no edema, grade 1 as <33.3% (minor extent),
grade 2 as >33.3% to <66.6% (moderate extent) and grade
3 as >66.6% (major extent). The signal intensity of the
edema was graded as 0 = no signal, 1 = low, 2 =moderate
and 3 = high signal intensity. With this method, the
maximum muscle edema score for each patient was 36
(18 for each thigh). Fatty replacement was scored accord-
ing to the grading system suggested by Gouttalier et al.
[27]; 0 = no fat, 1 = fatty streaks, 2 =muscle greater to fat,
3 =muscle equal to fat, 4 =muscle less to fat and 5 =
muscle totally replaced by fat (i.e., maximum possible
score 30). A Gouttalier score ≥ 2 in at least one com-
partment was considered pathological. Fascial edema
was defined as an abnormal thick deep fascial layer
with increased STIR signal, scored as present (1) or not
present (0-as was muscle volume reduction. The latter
was only noted when there were obvious findings:
asymmetry and/or disproportionate muscle compartments.
Two arbitrary scores were derived from this assessment:
(A) a total edema score with a maximum score of 42 con-
sisting of three components—edema extent (18), edema in-
tensity (18) and presence of fascial edema (6); and (B) a
total damage score (maximum score 36) including fatty re-
placement (30) and presence of muscle volume reduction
(6). Adding A and B gave a total MRI score of 42 + 36 = 78.
Evaluation of muscle strength and endurance
Muscle strength and muscle endurance were evaluated
by two experienced physiotherapists. For muscle strength,
the manual muscle test (MMT) ad modum Kendall et al.
[28] was used—tested on 14 muscles (MMT14, maximum
score 140) on the participants’ dominant side. The
MMT14 included neck flexion/extension and peripheral
and proximal muscle groups in the upper and lower ex-
tremities. For direct comparison with the MRI thigh scans,
we derived a MMT4 score (maximum score 40) which
included four muscles involved in hip flexion/abduction
and knee flexion/extension. A slightly modified Func-
tional Index test (FI2) [29] was used to evaluate muscle
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endurance, using 30 instead of 60 repetitions of neck
flexion (maximum score 330).
Muscle enzymes
Plasma creatinine kinase levels (P-CK) were measured in
units per liter and were considered pathological if >2
times upper limit of normal (2ULN). For the ASS pa-
tients, CK values at the time of diagnosis were collected
retrospectively from medical records.
Statistical analysis
IBM SPSS, version 22.0 was used for statistical analyses.
Normal distributed variables’ descriptive data were pre-
sented as mean and standard deviation (SD) and non-
normal distributed variables were presented as median with
range. Differences in continuous variables were evaluated
with Student’s t test (using paired samples T-test) for nor-
mally distributed data, and with Wilcoxon and Mann–
Whitney U tests for non-normally distributed data. Associ-
ations between categorical variables were detected by the
chi-square test. Correlations between MRI scores, CK
values, MMT scores and FI2 scores were evaluated by Pear-
son correlation, and between MRI scores and subgroups of
ASS by Spearman rank correlation. Multiple linear regres-
sion analyses were used to evaluate possible associations
between clinical variables and MRI muscle outcome.
Results
Patient characteristics
The ASS study cohort included 45 women and 23 men
(53 with anti-Jo1, six with PL-7 and nine with PL-12
antibodies) with mean (SD) age of 47 years (13.8) at
diagnosis. Median disease duration was 71 months
(range 6–362). Altogether, 54 of the 68 patients (79%)
had been diagnosed with myositis by their treating
physician prior to study inclusion; 27 with PM, 25 with
DM and two with hypomyopathic/amyopathic DM. For
comparison, 97% were diagnosed with ILD [23]. The 54
ASS patients with a prior myositis diagnosis had longer
median disease duration (76 months, range 6–232) than
the 14 cases without myositis (22 months, range 7–230;
p < 0.001). ASS patients positive for anti-Jo1 had myositis
more often than the Jo1-negative patients (p < 0.001;
Additional file 1: Figure S1). At study inclusion, 52/68
patients (75%) were on at least one disease-modifying
drug (± oral steroids), 10 patients were on prednisolone
as monotherapy and six patients did not use any im-
mune modulating treatment.
Muscle MRI findings in ASS versus age and sex-matched
controls
All controls (N = 67) and 66/68 ASS patients underwent
MRI of the thigh muscles (Fig. 1). Two patients were un-
able to complete the examination due to claustrophobia.
Defined MRI abnormalities were identified in 65% of the
patients and 22% of the controls (p < 0.001). In 26% of
the patients there were concomitant edema and muscle
damage changes, compared with 1.5% of the controls
(p < 0.001). Muscle edema was more frequent in patients
(38%) than in controls (12%) (p < 0.001), as was fatty re-
placement (42% versus 4%; p < 0.001) (Fig. 2). The magni-
tude of changes differed between patients and controls;
muscle edema score > 4 was present in 20 patients
(p < 0.001), but only in three of the controls; and fatty re-
placement score ≥ 6 was seen in 40 patients and 11 con-
trols (p < 0.001). Fascial edema was present in 29% of the
ASS patients and in 6% of the controls (p < 0.001). Sixteen
of the 19 ASS patients with fascial edema had known
myositis. Muscle volume reduction was evident in nine
patients (14%) and five controls (7%) (p < 0.250). In four
patients and five controls the MRI changes were asym-
metric. Total MRI score ranged from 0 to 47 in the ASS
patients, compared to 0 to 22 in the controls (Fig. 3a).
Total MRI score ≥ 10 was found in 31 patients and four
controls (p < 0.001). Total edema score ranged from 0 to
38 and from 0 to 16 in the ASS patients and controls, re-
spectively, and the range of total damage score was 0–18
in the patients and 0–8 in the controls (Fig. 3b, c). Com-
pared with the controls, the ASS patients scored signifi-
cantly higher in all three scores (total MRI, total edema
and total damage) (Table 1 and Fig. 3).
Distribution of MRI changes in the ASS patients
Muscle MRI changes were most common in the poster-
ior compartment followed by the anterior and medial
compartments (Fig. 4). Muscle edema was most promin-
ent in the anterior compartment, evident in 1/3 of the
patients, while fatty replacement was seen mostly poster-
iorly (in 36% of the patients) (Fig. 4). Fascial edema was
distributed almost equal in the three compartments in
about 21% of the patients.
MRI muscle findings in different ASS subgroups
In ASS patients previously diagnosed with myositis, MRI
changes were identified in 35/53 patients (66%); 10/53
(19%) had a total MRI score = 0. Mean (SD) total MRI
scores were 15.9 (14.67) in the myositis group and 5.5
(3.57) in the no myositis group (p < 0.001) (Table 2). Un-
expectedly, 5/13 of the ASS patients in the no myositis
group had MRI changes consistent with muscle inflam-
mation and/or muscle damage. Muscle strength and en-
durance did not differ between the groups (Table 2).
When dividing the ASS patients into anti-Jo-1-positive
and anti-Jo-1-negative groups, the results of MRI abnor-
malities, CK levels and muscle strength corresponded to
those of the myositis/no myositis groups (Table 2).
The only MRI score item that differed between PM
and DM subsets was muscle edema, where DM patients
Andersson et al. Arthritis Research & Therapy  (2017) 19:17 Page 3 of 9
scored significantly higher than PM patients (p < 0.039;
Table 2). Fascial edema was equally frequent in PM and
DM (present in eight patients in each group).
Subgroup segregation by treatment showed that pa-
tients with ongoing steroid treatment (N = 57) had lower
scores of muscle edema (p < 0.014) and, consequently,
total edema score (p < 0.044) than patients without ste-
roids (N = 9; data not shown). No correlation was found
between steroid treatment, muscle volume reduction or
total damage score.
The six patients without any immune suppressive
treatment all had known myositis and normal CK
values at study inclusion. These six patients had a me-
dian (range) total MRI score of 26.5 (0–39) with a me-
dian (range) total edema score of 23.5 (0–27) (data
not shown).
Fig. 1 a Muscle MRI with coronary STIR sequence of the thighs in a patient with ASS. Compared with surrounding tissue, the muscles are generally
brighter in color, most evident in the medial compartment (arrow), indicating general edema. The patient was scored with 36/36 points in the muscle
edema score. b The correspondent control to the patient in (a) with less color difference between muscles and surrounding tissue indicating no
muscle edema (score 0). c Axial T1-weighted image in an ASS patient with almost total fatty replacement anteriorly (Gouttalier score 4, light arrow) and
fatty streaks with more muscle than fat tissue (Gouttalier score 2, dark arrow) posteriorly. d The correspondent control to the patient in (c) evaluated as
normal muscle tissue (Goutallier score 0–1)
Fig. 2 Proportions of ASS patients (left: blue bars) and controls (right: red bars) with muscle edema, fascial edema, fatty replacement and muscle
volume reduction. ASS anti-synthetase syndrome (Color figure online)
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Plasma CK levels in ASS patients and controls
Plasma CK analyses were performed in 67 patients and
65 controls. No significant difference was found in me-
dian (range) CK levels between the groups (Table 1).
Only 4/67 ASS patients and 1/65 controls had CK
levels > 2 × ULN. Levels of CK correlated with total
edema score in the ASS patients (r = 0.501, p < 0.01) but
not in the controls (data not shown). Still, 23% of the
ASS patients with a normal CK had total edema score >
18. All of these patients had established myositis. Retro-
spective CK data from the time of the ASS diagnosis
was available in 55 patients. At diagnosis these patients
had a median CK level of 308 (range 20–14,900), com-
pared to 95 (range 24–1344) at study inclusion (p < 0.002).
The CK values at diagnosis did not correlate with total
edema score or total damage score.
Muscle strength and endurance
The ASS group had significantly lower MMT14, MMT4
and FI2 scores than the matched controls (Table 1). In
the ASS patients, significant correlations were seen be-
tween total damage score, MMT14 (r = –0.340, p < 0.01),
MMT4 (r = –0.344, p < 0.01) and the FI2 test (r = –0.484,
p < 0.01). None of the three muscle strength tests corre-
lated with the total edema score.
Factors associated with muscle activity and damage in ASS
In multiple linear regression analyses, the total edema
score was associated with pathological CK levels (p < 0.001)
and with anti-Ro52 and anti-Jo1 positivity (p < 0.016
and p < 0.036, respectively). No association was seen
with age, gender, disease duration, CK levels at diagnosis
or ongoing treatment. The total damage score in ASS was
associated with age (p < 0.002) and disease duration
(p < 0.015).
Discussion
Data on muscle MRI findings and muscular outcome in
ASS are limited. Here we showed that MRI findings com-
patible with either muscle damage (i.e. fatty replacement
Fig. 3 Median with interquartile range in ASS patients and controls for total MRI score (0–78), total edema score (0–42) and total damage score
(0–36). All three scores showed significant differences between the two groups. ASS anti-synthetase syndrome, MRI magnetic resonance imaging
Table 1 Muscle MRI scores and muscle parameters in ASS patients and controls
Muscle MRI scores ASS (N = 66) Controls (N = 67) p value
Total edema score (0–42)
Edema extent score (0–18) 3.2 (5.3) 0.4 (1.4) <0.001
Edema signal intensity score (0–18) 3.1 (5.0) 0.5 (1.7) <0.001
Fascial edema score (0–6) 1.3 (2.1) 0.1 (0.4) <0.001
Total damage score (0–36)
Fatty replacement score (0–30) 5.8 (4.3) 1.8 (2.4) <0.001
Muscle volume reduction score (0–6) 0.6 (1.6) 0.1 (0.6) <0.036
Total MRI score (activity + damage; 0–78) 14.1 (14.1) 3.0 (4.2) <0.001
Other muscle parameters
Median CK, U/L (range) 95 (24–1344) 98 (35–839) <0.676
CK > 2 × ULN, n/N (%) 4/67 (6) 1/65 (2) <0.366
Median MMT14 score (25th, 75th centile) 139 (133, 140) 140 (138, 140) <0.001
Median MMT4 score (25th, 75th centile) 40 (36, 40) 40 (39, 40) <0.004
Median FI2 score (25th, 75th centile) 211 (116, 301) 324 (281, 330) <0.001
Values presented as mean (SD) if not stated otherwise
ASS anti-synthetase syndrome, CK creatinine kinase, ULN upper limit of normal, MMT4 manual muscle test of four muscles, MMT14 manual muscle test of 14 muscles,
FI2 functional index, MRI magnetic resonance imaging
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Fig. 4 Accumulated numbers of MRI abnormalities identified in ASS patients (N = 66) and controls (N = 67). Because each person could have more
than one type of MRI abnormality, the accumulated number of abnormalities exceeds the number of patients. The two panels to the left show the
overall numbers (total) with muscle edema (blue), fascial edema (red), fatty replacement (green) and muscle volume reduction (violet), while the six
panels to the right show the number of abnormalities in the anterior, posterior and medial compartments. Contr controls (Color figure online)
Table 2 Demographics and MRI changes in subgroups of the ASS cohort
Myositis diagnosis prior to inclusion Anti-Jo-1 positivity Myositis subtype
Yes (N = 54) No (N = 14) p value Yes (N = 53) No (N = 15) p value PM (N = 27) DMa (N = 25) p value
Age at diagnosis
(years)
47 (14.3) 49 (11.5) n.s. 48 (13.9) 43 (12.8) n.s. 50 (14.9) 43 (13.7) n.s.
Disease duration
(months)
76 (6–362) 22 (7–230) 0.003 76 (6–362) 35 (7–230) 0.004 70 (6–362) 83 (14–350) n.s.
Jo1/non-Jo1, n 49 / 5 4 / 10 <0.001 25 / 2 23 / 2 n.s.
Ro-52 positivity,
n/N (%)
38/54 (70) 7/14 (50) n.s. 37/53 (70) 8/15 (53) n.s. 17/27 (63) 17/25 (68) n.s.
CK (U/L) 103 (38–1344) 71 (24–194) n.s. 101 (38–1344) 70 (24–572) n.s. 101 (43–437) 113 (38–1344) n.s.
MMT14 score (0–140) 139 (134, 140) 136 (127, 140) n.s. 139 (134, 140) 139.5 (131.5,140) n.s. 139 (136, 140) 137 (134, 140) n.s.
MMT4 score (0–40) 40 (36, 40) 38.5 (34, 40) n.s. 39 (36, 40) 40 (35, 40) n.s. 40 (37, 40) 39 (36, 40) n.s.




7.49 (10.7) 0.62 (1.5) <0.001 7.86 (10.7) 0.27 (1.0) <0.001 0 (0–26) 4 (0–36) 0.039
Total edema score
(0–42)
8.83 (12.0) 1.38 (2.5) <0.001 9.29 (12.1) 0.80 (2.2) <0.001 6.0 (9.6) 11.6 (13.8) n.s.
Total damage score
(0–36)
6.98 (5.4) 4.15 (2.5) 0.008 7.06 (5.5) 4.27 (2.7) 0.010 7.0 (5.7) 7.1 (5.1) n.s.
Total MRI score
(0–78)
15.87 (14.7) 5.54 (3.6) <0.001 16.39 (14.7) 5.13 (3.8) <0.001 13.0 (13.0) 18.8 (15.6) n.s.
Data presented as mean (SD), median (range) and median (25th, 75th centile) unless indicated otherwise
Data is presented as mean (SD) or median (range). For MMT14, MMT4 and FI2 data is presented with median (25th, 75th percentile)
aExcept for two patients with amyopathic DM
ASS anti-synthetase syndrome, MRI magnetic resonance imaging, PM polymyositis, DM dermatomyositis, n.s. not significant, CK creatinine kinase, MMT4 manual
muscle test of four muscles, MMT14 manual muscle test of 14 muscles, FI2 functional index
Bold text refers to significant differences
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and/or reduction in muscle volume) or active myositis
(edema in muscle and/or fascia) were present in 65% of
the patients in an ASS cohort with a median 6 years of
disease duration. Highly significant differences between
patients and healthy controls were seen in all MRI muscle
parameters, muscle strength and endurance.
Muscle MRI has been performed in a number of dif-
ferent muscle conditions, using semiquantitative and
quantitative methods [30–34]. Taken together, these data
indicate that some considerations should be made when
evaluating muscle MRI in myositis. First, muscle MRI
changes do not have to represent myositis. In this study,
we also identified edema, fatty replacement and volume
reduction in the healthy controls. However, the MRI
changes in healthy controls were much less pronounced
than in the patients; only three controls had a muscle
edema score > 4 and only one control had concomitant
signs of muscle edema and damage. Two controls had
edema evaluated as post-traumatic changes, a well-known
cause of MRI muscle edema [35]. The four controls with
total MRI score ≥ 10 were all over 70 years of age. This is
relevant because the total MRI score in the controls
correlated with age at study inclusion. Second, muscle
MRI changes can also be influenced by gender, espe-
cially muscle volume. Because no definitions of normal
muscle volumes exist, muscle atrophy is difficult to as-
sess. By using healthy controls matched for gender, and
a method which would underestimate rather than over-
estimate muscle atrophy, we tried to reduce this prob-
lem of interpretation. However, we still believe that the
data on muscle volume reduction must be interpreted
with some caution. Interestingly, we discovered a high
frequency of fatty streaks (Gouttalier score = 1) in muscle
compartments both in patients (33%) and in controls
(40%). Not surprisingly, the frequency of fatty streaks (and
the fatty replacement score) also correlated with age at
study inclusion in both groups, possibly indicating that a
“minor extent” of fatty replacement could be a natural
finding in muscle anatomy.
The current study did not reveal any specific ASS-
related MRI pattern equivalent to the recently described
ASS-related muscle histology pattern with necrotic myo-
fibers in the perimysium and inflammation in adjacent
connective tissue [21, 22]. However, some potentially in-
teresting observations were made. First, we found that
16 patients (eight PM and eight DM) were described
with fascial edema and 13/16 of these had concurrent
muscle edema. Previously, fascial edema has mostly been
described in DM and found to correlate with histopatho-
logical findings [13, 36]. We speculate that the observed
MRI pattern with concurrent edema in muscle and
fascia is a feature of active ASS, regardless of PM/DM
subset, but this needs to be evaluated in further studies.
Second, we found a trend toward partition of the MRI
findings, with predominance of fatty replacement in the
posterior compartment and muscle edema in the anterior
compartment. Because this study had a cross-sectional
design, we do not know whether the more pronounced
damage in the posterior musculature was a consequence
of relatively early and/or intense inflammation in this
compartment. Interestingly, fatty replacement (Gouttalier
score ≥ 2) was also present in a small number of the con-
trols (N = 3), all in the posterior part of the thighs, so these
findings need to be further investigated. A similar MRI
pattern, with edema anteriorly and fatty replacement
posteriorly, has recently been described in PM patients,
including patients with immune-mediated necrotizing
myopathy (IMNM) [14, 30].
The total edema score correlated with CK levels. This
is consistent with recent data from Italy where muscle
edema and CK correlated in 51 IIM patients [37]. How-
ever, in contrast to other studies [37, 38], there was no
correlation between the three muscle tests evaluated and
the total edema score. Instead, we found that muscle
strength correlated with the total damage score. Hence,
it is possible that the current study design, with cross-
sectional evaluation of patients with established disease,
is most suitable for MRI assessment of chronic muscle
changes. It should, however, be noted that 26% of the
ASS patients with visible muscle damage had concurrent
signs of activity (edema), and that 23% of the ASS pa-
tients, all with normal CK values, had a total edema
score ≥ 43% of maximum. Because muscle edema was
also seen in 12% of the controls (all but one with
normal CK values), one could discuss the clinical im-
portance of this finding. It should, however, be noted
that the extent and intensity of edema in the controls
was far less than in the patients. In fact, the 90th
centile of total edema score in the controls was only
4, compared to 26 in the patients. In addition, the
fact that the ASS patients with no previous myositis
diagnosis (N = 13) had higher MRI scores than their
correspondent healthy control (p < 0.02) emphasizes the
importance of muscle MRI to evaluate the possibility of
late-onset/subclinical myositis in ASS.
It has earlier been described that anti-Ro52 is associ-
ated with poor outcome in ASS-related ILD [39, 40],
and Marie et al. [41] have also reported anti-Ro52 as a
prognostic factor for the muscle component in the syn-
drome. This was also seen in the current study, independ-
ently of anti-Jo1 status (p < 0.05). Hence, anti-Ro52 seems
to be a possible prognostic factor for both the lung and
muscle components in ASS. Furthermore, subgroup
analyses showed an association between anti-Jo1 posi-
tivity and total edema score in the patients with earlier
diagnosed myositis. These findings should be evaluated
carefully, however, since the anti-Jo-1-negative myositis
group was small (N = 5).
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The study has some potential limitations. First, the
cross-sectional study design limits evaluation of potential
predictive muscle MRI variables and the progression of
these. Second, muscle endurance was also tested in
muscle groups other than thigh muscles; it is therefore
possible that whole-body MRI could correlate better
with the FI2 test. Third, we did not specifically investigate
possible associations between different kinds of treatment,
MRI findings and muscular functions in the ASS patients.
Conclusions
This comparative study showed that ASS patients, after
a median disease duration of nearly 6 years, had significantly
more muscle edema, fascial edema, fatty replacement and
muscle volume reduction than age and gender-matched
controls. The study emphasizes MRI as an independent tool
in the assessment of ASS-related myositis; particularly in
cases with normal CK. Prospective studies are needed
to determine the predictive values of MRI activity signs
and the rules governing progression of MRI damage
items.
Additional file
Additional file 1: Figure S1. showing the distribution of myositis subsets
in ASS patients with and without anti-Jo1 antibodies. Blue polymyositis (PM),
light blue dermatomyositis (DM), red clinical amyopathic dermatomyositis
(CADM) and yellow no myositis. (TIF 31 kb)
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